Page last updated: 2024-12-04

benzo(b)thiophene-2-boronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzo(b)thiophene-2-boronic acid: inhibits AmpC beta-lactamase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2359
CHEMBL ID34964
SCHEMBL ID8212
MeSH IDM0297555

Synonyms (67)

Synonym
1-benzothiophen-2-ylboronic acid, 18
bdbm26139
1-benzothiophen-2-ylboranediol
chembl34964 ,
benzo[b]thiophene-2-boronic acid
benzo[b]thien-2-ylboronic acid
DB04360
98437-23-1
NCGC00092008-01
benzothiophene-2-boronic acid
B2893
benzo[b]thiophen-2-boronic acid
bnezo[b]thiophen-2-boronic acid
benzo[b]thiophen-2-ylboronic acid
benzo[b]thiophene2-boronic acid
thianaphthene-2-boronic acid
1-benzothiophen-2-ylboronic acid
STK893402
inchi=1/c8h7bo2s/c10-9(11)8-5-6-3-1-2-4-7(6)12-8/h1-5,10-11h
yncypmujddxirh-uhfffaoysa-
benzo(b)thiophene-2-boronic acid
AKOS003585292
NCGC00092008-02
2-benzothienylboronic acid
2-benzothienylboronic acid;benzo[b]thiophen-2-ylboronic acid
FT-0622687
AB08143
3FKV
BBL020712
AB01332905-02
benzo[b]thiophene-2-ylboronic acid
SCHEMBL8212
3IXG
mfcd01075674
SY001173
1-benzothien-2-ylboronic acid
(2-benzo[b]thienyl)boronic acid
YNCYPMUJDDXIRH-UHFFFAOYSA-N
2-benzothienyl boronic acid
1-benzothiophen-2-yl-boronic acid
2-benzo[b]thiopheneboronic acid
bezothiophene-2-boronic acid
benzo[b]thiophen-2-yl-2-boronic acid
benzo[b]-thiophene-2-boronic acid
2-benzothiopheneboronic acid
2-benzo[b]thiophene boronic acid
benzothiophen-2-boronic acid
benzothiopheneboronic acid
thianapthene-2-boronic acid
benzo(b) thiophene-2-boronic acid
HMS3604C07
boronic acid, benzo[b]thien-2-yl-
J-519698
DTXSID80274363
CS-W018486
NCGC00092008-03
benzo[b]thiophene-2-boronicacid
Z1255488387
SME05QG1FJ ,
benzo(b)thiophen-2-ylboronic acid
unii-sme05qg1fj
Q27095165
benzo[b]thiophene-2-ylboronic acid, (contains varying amounts of anhydride)
AS-15065
benzo[b]thiophene-2-boronic acid (contains varying amounts of anhydride)
(1-benzothiophen-2-yl)boronic acid
EN300-212491
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency7.07950.000811.382244.6684AID686978
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
Alpha-synucleinHomo sapiens (human)Potency35.48130.56239.398525.1189AID652106
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain B, Beta-lactamaseEscherichia coli K-12Ki0.02700.02700.02700.0270AID977610
B2 bradykinin receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.20000.00112.58648.0000AID43124
Acyl-protein thioesterase 1Homo sapiens (human)IC50 (µMol)1.41450.00251.17613.5500AID1799826
Acyl-protein thioesterase 2Homo sapiens (human)IC50 (µMol)1.41450.01961.28733.5500AID1799826
Chymotrypsinogen ABos taurus (cattle)IC50 (µMol)5.00000.98004.05607.2000AID36989
Beta-lactamaseEscherichia coli K-12IC50 (µMol)0.20830.01502.46578.0000AID218575; AID218680; AID218681; AID218682; AID38396; AID43124
Beta-lactamaseEscherichia coli K-12Ki0.02700.02703.64137.3000AID38397; AID38398
Trypsin-2Homo sapiens (human)IC50 (µMol)200.00000.00351.58464.4000AID44381
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)2.60000.00031.38338.4000AID36989; AID43124
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00051.48357.8000AID36989
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00311.73607.8000AID36989
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00501.79627.8000AID36989
Angiotensin-converting enzymeRattus norvegicus (Norway rat)Ki0.02700.00011.96427.3000AID38398
Beta-lactamase TEMEscherichia coliKi0.02700.02701.82347.3000AID303336
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)10.76670.00051.33138.0000AID1798637; AID346655
Monoglyceride lipaseHomo sapiens (human)IC50 (µMol)21.38330.00091.126810.0000AID1798637; AID346656
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (103)

Processvia Protein(s)Taxonomy
protein depalmitoylationAcyl-protein thioesterase 1Homo sapiens (human)
fatty acid metabolic processAcyl-protein thioesterase 1Homo sapiens (human)
fatty acid transportAcyl-protein thioesterase 1Homo sapiens (human)
negative regulation of Golgi to plasma membrane protein transportAcyl-protein thioesterase 1Homo sapiens (human)
negative regulation of aggrephagyAcyl-protein thioesterase 1Homo sapiens (human)
protein depalmitoylationAcyl-protein thioesterase 2Homo sapiens (human)
fatty acid metabolic processAcyl-protein thioesterase 2Homo sapiens (human)
axon guidanceAcyl-protein thioesterase 2Homo sapiens (human)
acylglycerol catabolic processAcyl-protein thioesterase 2Homo sapiens (human)
prostaglandin catabolic processAcyl-protein thioesterase 2Homo sapiens (human)
digestionChymotrypsinogen ABos taurus (cattle)
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
proteolysisTrypsin-2Homo sapiens (human)
digestionTrypsin-2Homo sapiens (human)
antimicrobial humoral responseTrypsin-2Homo sapiens (human)
extracellular matrix disassemblyTrypsin-2Homo sapiens (human)
positive regulation of cell growthTrypsin-2Homo sapiens (human)
collagen catabolic processTrypsin-2Homo sapiens (human)
positive regulation of cell adhesionTrypsin-2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
lipid metabolic processMonoglyceride lipaseHomo sapiens (human)
fatty acid biosynthetic processMonoglyceride lipaseHomo sapiens (human)
inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of signal transductionMonoglyceride lipaseHomo sapiens (human)
arachidonic acid metabolic processMonoglyceride lipaseHomo sapiens (human)
triglyceride catabolic processMonoglyceride lipaseHomo sapiens (human)
acylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of sensory perception of painMonoglyceride lipaseHomo sapiens (human)
monoacylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of endocannabinoid signaling pathwayMonoglyceride lipaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
phospholipase activityAcyl-protein thioesterase 1Homo sapiens (human)
lysophospholipase activityAcyl-protein thioesterase 1Homo sapiens (human)
protein bindingAcyl-protein thioesterase 1Homo sapiens (human)
palmitoyl-(protein) hydrolase activityAcyl-protein thioesterase 1Homo sapiens (human)
lipase activityAcyl-protein thioesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityAcyl-protein thioesterase 1Homo sapiens (human)
lysophospholipase activityAcyl-protein thioesterase 2Homo sapiens (human)
protein bindingAcyl-protein thioesterase 2Homo sapiens (human)
palmitoyl-(protein) hydrolase activityAcyl-protein thioesterase 2Homo sapiens (human)
cadherin bindingAcyl-protein thioesterase 2Homo sapiens (human)
carboxylic ester hydrolase activityAcyl-protein thioesterase 2Homo sapiens (human)
protein bindingChymotrypsinogen ABos taurus (cattle)
serpin family protein bindingChymotrypsinogen ABos taurus (cattle)
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
metalloendopeptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-2Homo sapiens (human)
calcium ion bindingTrypsin-2Homo sapiens (human)
protein bindingTrypsin-2Homo sapiens (human)
serine-type peptidase activityTrypsin-2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
lysophospholipase activityMonoglyceride lipaseHomo sapiens (human)
protein bindingMonoglyceride lipaseHomo sapiens (human)
protein homodimerization activityMonoglyceride lipaseHomo sapiens (human)
acylglycerol lipase activityMonoglyceride lipaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
plasma membraneAcyl-protein thioesterase 1Homo sapiens (human)
nucleoplasmAcyl-protein thioesterase 1Homo sapiens (human)
cytoplasmAcyl-protein thioesterase 1Homo sapiens (human)
endoplasmic reticulumAcyl-protein thioesterase 1Homo sapiens (human)
cytosolAcyl-protein thioesterase 1Homo sapiens (human)
plasma membraneAcyl-protein thioesterase 1Homo sapiens (human)
nuclear membraneAcyl-protein thioesterase 1Homo sapiens (human)
extracellular exosomeAcyl-protein thioesterase 1Homo sapiens (human)
cytoplasmAcyl-protein thioesterase 1Homo sapiens (human)
nucleoplasmAcyl-protein thioesterase 2Homo sapiens (human)
cytoplasmAcyl-protein thioesterase 2Homo sapiens (human)
Golgi stackAcyl-protein thioesterase 2Homo sapiens (human)
cytosolAcyl-protein thioesterase 2Homo sapiens (human)
extracellular exosomeAcyl-protein thioesterase 2Homo sapiens (human)
cytoplasmAcyl-protein thioesterase 2Homo sapiens (human)
extracellular regionChymotrypsinogen ABos taurus (cattle)
serine protease inhibitor complexChymotrypsinogen ABos taurus (cattle)
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
extracellular regionTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular matrixTrypsin-2Homo sapiens (human)
azurophil granule lumenTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
endoplasmic reticulum membraneMonoglyceride lipaseHomo sapiens (human)
cytosolMonoglyceride lipaseHomo sapiens (human)
plasma membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID303336Inhibition of Escherichia coli beta-lactamase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy.
AID228517Aggregates forming ability by dynamic light scattering(DLS).2002Journal of medicinal chemistry, Apr-11, Volume: 45, Issue:8
A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.
AID1154638Competitive inhibition of Escherichia coli beta-lactamase AmpC using nitrocefin as substrate by UV-Vis spectrophotometry2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative.
AID43258Percentage inhibition against beta-Lactamase in the presence of detergent 0.01% Triton X-100 was determined at a concentration of 0.6 uM2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
A specific mechanism of nonspecific inhibition.
AID38397Binding affinity towards AmpC beta-lactamase binding site from Escherichia coli2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Structure-based approach for binding site identification on AmpC beta-lactamase.
AID218681Inhibitory activity against beta-lactamase in the presence of 50 mM KPi concentration of buffer2002Journal of medicinal chemistry, Apr-11, Volume: 45, Issue:8
A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.
AID38396Compound was tested for its specificity against AmpC beta-lactamase1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID43248Percentage inhibition against beta-Lactamase in the absence of detergent Triton X-100 was determined at a concentration of 0.6 uM2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
A specific mechanism of nonspecific inhibition.
AID218690Decrease in inhibition of beta-lactamase due to 10-fold increase in enzyme concentration; No change2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID67675Compound was tested for its specificity against Elastase1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID303338Antibacterial activity against Escherichia coli K12 JM109 overexpressing beta-lactamase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy.
AID43124Inhibitory activity against Amp C beta-Lactamase2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
A specific mechanism of nonspecific inhibition.
AID346656Inhibition of human recombinant MGL2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase.
AID218682Inhibitory activity against beta-lactamase in the presence of 5 mM KPi concentration of buffer2002Journal of medicinal chemistry, Apr-11, Volume: 45, Issue:8
A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.
AID218680Inhibitory activity against beta-lactamase in the presence of 500 mMKPi concentration of buffer2002Journal of medicinal chemistry, Apr-11, Volume: 45, Issue:8
A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.
AID346655Inhibition of Wistar rat brain FAAH assessed as [3H]arachidonoylethanolamide hydrolysis2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase.
AID36989Compound was tested for its specificity against alpha-chymotrypsin1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID437825Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X assessed as residual activity at 1000 uM preincubated for 60 mins before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitroben2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors.
AID1154639Competitive inhibition of wild type beta-lactamase TEM-1 (unknown origin) expressed in Escherichia coli using 6-beta-furylacryloylamido-penicillanic acid as substrate by spectrophotometry2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative.
AID44381Compound was tested for its specificity against beta-trypsin1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID437828Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X assessed as residual activity at 1000 uM preincubated for 4 hrs before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitroben2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors.
AID437817Inhibition of Actinomadura sp. R39 penicillin-binding protein assessed as residual activity at 1000 uM preincubated for 60 mins before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitrobenzoic ac2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors.
AID218691Increase in inhibition of beta-lactamase due to the effect of incubation; No change2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID1154640Competitive inhibition of wild type beta-lactamase CTX-M-9 (unknown origin) expressed in Escherichia coli BL21(DE3) using 6-beta-furylacryloylamido-penicillanic acid as substrate by UV-Vis spectrophotometry2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative.
AID218679Inhibition of beta-lactamase from Escherichia coli2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID303337Dissociation constant, pKa of the compound2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy.
AID38398Inhibitory activity against Escherichia coli AmpC beta-lactamase.1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID218575Inhibitory activity against beta-lactamase2002Journal of medicinal chemistry, Apr-11, Volume: 45, Issue:8
A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.
AID1799826Enzymatic Protein Activity Assay from Article 10.1002/cbic.201200571: \\Boron-based inhibitors of acyl protein thioesterases 1 and 2.\\2013Chembiochem : a European journal of chemical biology, Jan-02, Volume: 14, Issue:1
Boron-based inhibitors of acyl protein thioesterases 1 and 2.
AID1798637FAAH Inhibition Assay from Article 10.1021/jm801051t: \\Discovery of Boronic Acids as Novel and Potent Inhibitors of Fatty Acid Amide Hydrolase.\\2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2010Journal of molecular biology, Feb-12, Volume: 396, Issue:1
Structural bases for stability-function tradeoffs in antibiotic resistance.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (11.76)18.2507
2000's11 (64.71)29.6817
2010's4 (23.53)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.75 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]